{"groups":[{"description":"Arm 1: Dato-DXd","id":"FG000","title":"Dato-DXd"},{"description":"Arm 2: ICC (Capecitabine or Gemcitabine or Eribulin mesylate or Vinorelbine)","id":"FG001","title":"Investigator's Choice of Chemotherapy (ICC)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Reason unknown"},{"reasons":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"131"}],"type":"Ongoing in study at data cut-off date"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"29"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"214"},{"groupId":"FG001","numSubjects":"204"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"365"},{"groupId":"FG001","numSubjects":"367"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"365"},{"groupId":"FG001","numSubjects":"367"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}